EPS for Aethlon Medical, Inc. (AEMD) Expected At $-0.12; Motif Bio plc (LON:MTFB) Had 4 Bulls

January 18, 2018 - By Henry Gaston

Among 4 analysts covering Motif Bio Plc (LON:MTFB), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Motif Bio Plc had 82 analyst reports since July 23, 2015 according to SRatingsIntel. The stock of Motif Bio plc (LON:MTFB) has “Buy” rating given on Tuesday, January 16 by Northland Capital. The firm has “Speculative Buy” rating by Beaufort Securities given on Thursday, March 3. The company was maintained on Tuesday, August 16 by Northland Capital. The firm earned “Buy” rating on Wednesday, March 2 by Northland Capital. FinnCap maintained the stock with “Buy” rating in Tuesday, May 30 report. The stock of Motif Bio plc (LON:MTFB) earned “Speculative Buy” rating by Beaufort Securities on Monday, October 2. The stock of Motif Bio plc (LON:MTFB) has “Speculative Buy” rating given on Wednesday, April 19 by Beaufort Securities. The firm earned “Buy” rating on Thursday, July 6 by Northland Capital. The rating was maintained by Beaufort Securities with “Speculative Buy” on Friday, August 28. The stock has “Buy” rating by Peel Hunt on Friday, December 22. See Motif Bio plc (LON:MTFB) latest ratings:

16/01/2018 Broker: Northland Capital Rating: Buy Maintain
10/01/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 107.00 New Target: GBX 107.00 Maintain
05/01/2018 Broker: Northland Capital Rating: Buy Maintain
22/12/2017 Broker: Northland Capital Rating: Buy Maintain
22/12/2017 Broker: Peel Hunt Rating: Buy Maintain
21/11/2017 Broker: FinnCap Rating: Buy Old Target: GBX 100.00 New Target: GBX 100.00 Maintain
16/11/2017 Broker: Beaufort Securities Rating: Speculative Buy Old Target: GBX 110.00 New Target: GBX 110.00 Maintain
16/11/2017 Broker: FinnCap Rating: Buy Old Target: GBX 100.00 New Target: GBX 100.00 Maintain
15/11/2017 Broker: Northland Capital Rating: Buy Maintain
15/11/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 106.00 New Target: GBX 106.00 Maintain

Analysts expect Aethlon Medical, Inc. (NASDAQ:AEMD) to report $-0.12 EPS on February, 9.They anticipate $0.03 EPS change or 20.00% from last quarter’s $-0.15 EPS. After having $-0.14 EPS previously, Aethlon Medical, Inc.’s analysts see -14.29% EPS growth. The stock decreased 2.17% or $0.03 during the last trading session, reaching $1.35. About 205,467 shares traded. Aethlon Medical, Inc. (NASDAQ:AEMD) has declined 56.57% since January 18, 2017 and is downtrending. It has underperformed by 73.27% the S&P500.

The stock decreased 3.08% or GBX 1.2538 during the last trading session, reaching GBX 39.4462. About 508,416 shares traded. Motif Bio plc (LON:MTFB) has 0.00% since January 18, 2017 and is . It has underperformed by 16.70% the S&P500.

Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company has market cap of $20.38 million. The firm is developing Aethlon Hemopurifier, a clinical-stage therapeutic device for the single-use removal of life-threatening viruses from the circulatory system of infected individuals. It currently has negative earnings. It is also involved in the development of exosome products to diagnose and monitor neurological disorders and cancer; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>